Literature DB >> 3351421

Vasoactive intestinal peptide and the stimulation of lactotroph growth by oestradiol in rats.

R A Prysor-Jones1, J J Silverlight, S J Kennedy, J S Jenkins.   

Abstract

Treatment with a high dose of oestradiol for 6 months caused hyperprolactinaemia and pituitary hyperplasia in female Wistar-Furth rats. Changes in the vasoactive intestinal peptide (VIP) and dopamine content of the hypothalamus and pituitary were also found. The hypothalamic dopamine concentration was only slightly reduced and, although the concentration of dopamine in the pituitary was less in treated animals, the total pituitary content was increased. The concentration of VIP in the pituitary was increased by oestradiol treatment but decreased in the non-median eminence hypothalamus. In the median eminence the VIP content was increased by oestradiol treatment and the amount present correlated positively and significantly with pituitary wet weight in animals treated with both oestradiol and fluphenazine. In Fischer 344 rats, oestradiol produced greater incremental changes in pituitary wet weight and plasma concentrations of prolactin than in Wistar controls and the increase in the pituitary concentration of VIP was five times greater. Although peptide turnover has not been measured, these results suggest that oestradiol, as well as having a direct action, stimulates pituitary lactotrophs by increasing pituitary concentrations of VIP.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3351421     DOI: 10.1677/joe.0.1160259

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  4 in total

1.  Different ultrastructural localization of VIP and prolactin in anterior pituitary cells of rats chronically treated with estrogen.

Authors:  K Köves; I L Chen; T J Görcs; J G Scammell; A Arimura
Journal:  Endocrine       Date:  1996-10       Impact factor: 3.633

Review 2.  Towards a functional significance of peptides and biogenic amines produced by the anterior pituitary.

Authors:  H Houben; D Tilemans; C Denef
Journal:  J Endocrinol Invest       Date:  1990-11       Impact factor: 4.256

3.  Vasoactive intestinal peptide in the human pituitary gland and adenomas. An immunocytochemical study.

Authors:  D W Hsu; P N Riskind; E T Hedley-Whyte
Journal:  Am J Pathol       Date:  1989-08       Impact factor: 4.307

4.  Neonatal androgenization increases vasoactive intestinal peptide levels in rat anterior pituitary: possible involvement of vasoactive intestinal peptide in the neonatal androgenization-induced hyperprolactinemia.

Authors:  H Watanobe; S Sasaki; K Takebe
Journal:  J Endocrinol Invest       Date:  1991-11       Impact factor: 4.256

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.